WASHINGTON--A handful of potential witnesses in the upcoming trial of a former top UBS AG executive are refusing to travel to the U.S. to testify on behalf of the European banker out of fear they'll be arrested by U.S. law enforcement, according to court papers.

That sets the stage for rare testimony by videoconference in the tax evasion conspiracy trial of former UBS wealth management chief executive Raoul Weil, which begins Tuesday. Mr. Weil is the highest-ranking executive so far to face criminal charges as part of an ongoing U.S. crackdown on Swiss banks that help Americans hide assets from the Internal Revenue Service.

Prosecutors will try to convince a jury in Fort Lauderdale, Fla. that Mr. Weil aided the UBS wealth management group in a broad conspiracy to solicit deposits from wealthy Americans trying to avoid taxes and then employed cloak-and-dagger tactics to keep them secret.

Mr. Weil's lawyers have signaled in court papers and previous appearances they plan to argue their client--the No. 3 executive at UBS--paid little attention to the private banking group's U.S. cross-border banking business, which accounted for a fraction of his overall responsibilities.

To aid their client's case, Mr. Weil's attorneys plan to elicit testimony from several witnesses in Europe and South Africa. But, in a twist, those individuals won't be appearing in the Florida courtroom because they fear being ensnared in the government's case and possibly arrested.

Mr. Weil's attorneys initially asked the judge to let witnesses testify from Switzerland but the government opposed that move, in part because Swiss law presented complications--including a ban on U.S. law enforcement conducting official acts in that country. The two sides agreed to allow some testimony from London and the witnesses will appear on a screen in the courtroom. The witnesses' names and affiliations haven't been released.

The case against Mr. Weil represents a rare instance of a high-ranking executive at a big financial institution facing a criminal charge in connection with widespread conduct that allegedly occurred beneath him. Mr. Weil, who was indicted in 2008, is the first target of the tax-evasion probe to take his case to a jury. So far, a handful of other bankers pleaded guilty to charges, while others received nonprosecution agreements in return for their cooperation. One former UBS Americas banker, Martin Liechti, spent four months at a Four Seasons Hotel talking to prosecutors after being detained on a material witness warrant in Miami in 2008. He's expected to testify against Mr. Weil.

In court papers, his lawyers argue the U.S. only indicted Mr. Weil to scare both UBS and the Swiss government, which had prevented the bank from turning over customer names. But jurors might not hear that argument. Prosecutors have argued in court papers that its motives for bringing a case against Mr. Weil are irrelevant to his guilt or innocence.

UBS has also cooperated with the government. It agreed in 2009 to pay $780 million, cooperate with investigators and turn over some client names to settle U.S. allegations that it aided tax evasion. In May, Credit Suisse Group AG became the first financial institution in nearly a decade to plead guilty to a crime when it agreed to pay $2.6 billion and admit to conspiring to aid tax evasion.

Mr. Weil, a Swiss national, remained free for five years after his indictment. He was arrested late last year after he checked into a hotel in Bologna, Italy and police--following a new procedure--checked the guest register against outstanding warrants. He was extradited in January.

In cases like the one against Mr. Weil, "given the defendant's position and his level of education and intelligence, it can often be hard for the defense to convince a jury that the person didn't know what was going on or wasn't involved," said Peter Hardy, a principal at the law firm Post & Schell who spent five years in the Justice Department's tax division.

Write to Andrew Grossman at andrew.grossman@wsj.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

THC Farmaceuticals (PK) (USOTC:CBDG)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more THC Farmaceuticals (PK) Charts.
THC Farmaceuticals (PK) (USOTC:CBDG)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more THC Farmaceuticals (PK) Charts.